Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220817 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study
A Phase 2 study, sponsored by POM Wonderful.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT01220817 is a Phase 2 study that has completed, run by POM Wonderful. The registered enrollment target is 104 participants.
The verdict
NCT01220817, a Phase 2 study, has completed, sponsored by POM Wonderful.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
When given to men with recurrent prostate cancer, the investigators hypothesize that POMx is effective in slowing the rise of PSA as measured by PSA doubling time in men following initial therapy for prostate cancer. Further, the investigators believe that POMx will be shown to be safe and well tolerated.
Interventions
- DRUG 3 POMx capsules
- DRUG 1 POMx capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01220817
The ClinicalTrials.gov registry entry for NCT01220817 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is POM Wonderful, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 3 POMx capsules is the first listed.
NCT01220817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01220817 about?
NCT01220817 is a clinical study titled "Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study". When given to men with recurrent prostate cancer, the investigators hypothesize that POMx is effective in slowing the rise of PSA as measured by PSA doubling time in men following initial therapy for prostate cancer. Further, the investigators believe that POMx will be shown to be safe and well tole...
What is the current status of trial NCT01220817?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2007-10. Estimated completion is 2010-05.
What interventions are being tested in trial NCT01220817?
The interventions under investigation include: 3 POMx capsules (DRUG), 1 POMx capsule (DRUG).
Who is sponsoring clinical trial NCT01220817?
This trial is sponsored by POM Wonderful, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.